| Special Drug Use-results Surveillance of Scemblix Tablets (NCT05421091) | Novartis Pharmaceuticals | 2022-07-04 |
| Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension (NCT05135000) | Novartis Pharmaceuticals | 2022-06-30 |
| A Post Marketing Surveillance on Piqray in Korea (NCT05293470) | Novartis Pharmaceuticals | 2022-06-29 |
| Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity (NCT05304949) | Novartis Pharmaceuticals | 2022-06-22 |
| Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy (NCT05376579) | Novartis Pharmaceuticals | 2022-06-17 |
| Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (NCT05132075) | Novartis Pharmaceuticals | 2022-06-15 |
| A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD) (NCT05358717) | Novartis Pharmaceuticals | 2022-06-03 |
| Burden of Illness and Treatment Assessment of Patients With Dry Eye Disease: A Cross-Sectional Survey of Real-World Patients With Dry Eye Disease in the US (NCT06018571) | Novartis Pharmaceuticals | 2022-06-02 |
| Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (NCT06184360) | Novartis Pharmaceuticals | 2022-05-31 |
| A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab (NCT06460324) | Novartis Pharmaceuticals | 2022-05-20 |
| A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. (NCT05155709) | Novartis Pharmaceuticals | 2022-05-17 |
| Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF) (NCT05328752) | Novartis Pharmaceuticals | 2022-05-17 |
| Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study (NCT05294289) | Novartis Pharmaceuticals | 2022-05-16 |
| Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study (NCT05285904) | Novartis Pharmaceuticals | 2022-05-12 |
| A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. (NCT05109728) | Novartis Pharmaceuticals | 2022-05-10 |
| A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma (NCT06337617) | Novartis Pharmaceuticals | 2022-05-10 |
| A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis (NCT05344469) | Novartis Pharmaceuticals | 2022-05-10 |
| A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea (NCT04946305) | Novartis Pharmaceuticals | 2022-05-10 |
| A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura® (NCT05217810) | Novartis Pharmaceuticals | 2022-05-09 |
| A 24-week rPMS Study in Real-world Setting for Enerzair (NCT05274425) | Novartis Pharmaceuticals | 2022-05-09 |
| Real-World Use of Novel Treatments in Patients With Spinal Muscular Atrophy (SMA): A Multi-Site Retrospective Chart Review of Pediatric SMA Patients Outside of the United States (NCT06178393) | Novartis Pharmaceuticals | 2022-05-05 |
| Effectiveness of Early Intervention in Transfusion Independent Aplastic Anemia: a Retrospective Medical Claims Database Study (NCT06669221) | Novartis Pharmaceuticals | 2022-05-05 |
| First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy Volunteers (NCT05275855) | Novartis Pharmaceuticals | 2022-04-29 |
| Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz (NCT05330273) | Novartis Pharmaceuticals | 2022-04-28 |
| The Belgian REAL (BE.REAL) Registry (NCT05726838) | Novartis Pharmaceuticals | 2022-04-15 |
| Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting (NCT05266495) | Novartis Pharmaceuticals | 2022-04-13 |
| Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter. (NCT05330286) | Novartis Pharmaceuticals | 2022-04-13 |
| Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia (NCT05192941) | Novartis Pharmaceuticals | 2022-04-08 |
| A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib in Turkey (NCT07357441) | Novartis Pharmaceuticals | 2022-04-07 |
| Study of Efficacy and Safety of ABO809 in Healthy Participants (NCT05036668) | Novartis Pharmaceuticals | 2022-04-07 |
| Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant (NCT04899349) | Novartis Pharmaceuticals | 2022-04-06 |
| 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis (NCT05155098) | Novartis Pharmaceuticals | 2022-03-25 |
| STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS (NCT04878432) | Novartis Pharmaceuticals | 2022-03-17 |
| A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy (NCT05853432) | Novartis Pharmaceuticals | 2022-03-16 |
| Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE) (NCT05203419) | Novartis Pharmaceuticals | 2022-03-15 |
| Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) (NCT05269966) | Novartis Pharmaceuticals | 2022-03-09 |
| Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir (NCT05236530) | Novartis Pharmaceuticals | 2022-03-09 |
| Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant (NCT04862143) | Novartis Pharmaceuticals | 2022-03-08 |
| To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria (NCT04675931) | Novartis Pharmaceuticals | 2022-03-07 |
| PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma (NCT05172596) | Novartis Pharmaceuticals | 2022-03-03 |
| A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation (NCT05090371) | Novartis Pharmaceuticals | 2022-03-02 |
| Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib (NCT05073120) | Novartis Pharmaceuticals | 2022-02-28 |
| A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration (NCT05230537) | Novartis Pharmaceuticals | 2022-02-17 |
| Adherence and Persistence to Inclisiran Among Early Users in Germany (NCT05870657) | Novartis Pharmaceuticals | 2022-02-16 |
| An Observational Prospective Study to Characterize Patients Initiating Enerzair® Breezhaler®, With or Without Sensor, as a Maintenance Treatment for Asthma (NCT05120986) | Novartis Pharmaceuticals | 2022-02-15 |
| Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP (NCT05215561) | Novartis Pharmaceuticals | 2022-02-14 |
| Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older). (NCT04230148) | Novartis Pharmaceuticals | 2022-02-11 |
| Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM (NCT05199090) | Novartis Pharmaceuticals | 2022-02-10 |
| Investigate Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers (NCT05195892) | Novartis Pharmaceuticals | 2022-02-03 |
| Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA) (NCT05089656) | Novartis Pharmaceuticals | 2022-02-01 |
| Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL) (NCT04456023) | Novartis Pharmaceuticals | 2022-01-31 |
| A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting (NCT05362903) | Novartis Pharmaceuticals | 2022-01-31 |
| Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1) (NCT04980833) | Novartis Pharmaceuticals | 2022-01-27 |
| Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan (NCT05114746) | Novartis Pharmaceuticals | 2022-01-25 |
| Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. (NCT05084638) | Novartis Pharmaceuticals | 2022-01-25 |
| Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (NCT04903197) | Novartis Pharmaceuticals | 2022-01-24 |
| Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (NCT04889430) | Novartis Pharmaceuticals | 2022-01-17 |
| A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines (NCT05048342) | Novartis Pharmaceuticals | 2022-01-15 |
| Treatment Patterns With Brolucizumab in Germany - a Retrospective Cohort Study Based on Longitudinal Prescription Data: REALIZE Study (NCT06021366) | Novartis Pharmaceuticals | 2022-01-07 |
| Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies (NCT05950308) | Novartis Pharmaceuticals | 2022-01-05 |
| A Retrospective Study to Evaluate the Early Real-world Evidence of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) in India (NCT05834075) | Novartis Pharmaceuticals | 2022-01-05 |
| Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP) (NCT06211153) | Novartis Pharmaceuticals | 2021-12-31 |
| Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia (NCT04925479) | Novartis Pharmaceuticals | 2021-12-27 |
| Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders (NCT05086744) | Novartis Pharmaceuticals | 2021-12-21 |
| LUTATHERA Injection General Use Result Survey (NCT05844332) | Novartis Pharmaceuticals | 2021-12-17 |
| Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1) (NCT05147220) | Novartis Pharmaceuticals | 2021-12-16 |
| Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent (NCT04933552) | Novartis Pharmaceuticals | 2021-12-15 |
| Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2) (NCT05156281) | Novartis Pharmaceuticals | 2021-12-13 |
| Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment (NCT04993157) | Novartis Pharmaceuticals | 2021-12-10 |
| Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Mutations (NCT05796726) | Novartis Pharmaceuticals | 2021-12-10 |
| Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (NCT05118230) | Novartis Pharmaceuticals | 2021-12-09 |
| A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease (NCT05111249) | Novartis Pharmaceuticals | 2021-12-08 |
| Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy (NCT04984876) | Novartis Pharmaceuticals | 2021-12-07 |
| Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors (NCT04795427) | Novartis Pharmaceuticals | 2021-12-06 |
| Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials (NCT05301907) | Novartis Pharmaceuticals | 2021-12-02 |
| A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines (NCT05032157) | Novartis Pharmaceuticals | 2021-12-01 |
| Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up (NCT06178770) | Novartis Pharmaceuticals | 2021-12-01 |
| Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma. (NCT04961619) | Novartis Pharmaceuticals | 2021-12-01 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD) (NCT04988087) | Novartis Pharmaceuticals | 2021-11-30 |
| Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL (NCT04156659) | Novartis Pharmaceuticals | 2021-11-30 |
| DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies (NCT04895748) | Novartis Pharmaceuticals | 2021-11-30 |
| A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines (NCT05030311) | Novartis Pharmaceuticals | 2021-11-30 |
| Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients (NCT05963282) | Novartis Pharmaceuticals | 2021-11-29 |
| A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) (NCT04737330) | Novartis Pharmaceuticals | 2021-11-29 |
| A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis (NCT05334472) | Novartis Pharmaceuticals | 2021-11-24 |
| Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants (NCT05026996) | Novartis Pharmaceuticals | 2021-11-23 |
| Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (NCT05030428) | Novartis Pharmaceuticals | 2021-11-23 |
| Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice (NCT05112835) | Novartis Pharmaceuticals | 2021-11-19 |
| Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study (NCT04895202) | Novartis Pharmaceuticals | 2021-11-19 |
| Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Itraconazole (NCT05084651) | Novartis Pharmaceuticals | 2021-11-18 |
| Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines (NCT05024058) | Novartis Pharmaceuticals | 2021-11-16 |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer (NCT04940052) | Novartis Pharmaceuticals | 2021-11-15 |
| Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function. (NCT05078580) | Novartis Pharmaceuticals | 2021-11-10 |
| Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India (NCT05020873) | Novartis Pharmaceuticals | 2021-11-04 |
| Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA) (NCT05073133) | Novartis Pharmaceuticals | 2021-11-04 |
| Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease (NCT04795466) | Novartis Pharmaceuticals | 2021-10-28 |
| Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world (NCT05022342) | Novartis Pharmaceuticals | 2021-10-27 |
| Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib (NCT05848219) | Novartis Pharmaceuticals | 2021-10-16 |
| Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib) (NCT04547946) | Novartis Pharmaceuticals | 2021-10-15 |
| Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab. (NCT04774926) | Novartis Pharmaceuticals | 2021-10-15 |